09.16.19

Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting

Source: Kodiak Sciences

09.12.19

Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for Wet AMD

Source: Kodiak Sciences

09.11.19

Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercept

Source: Novartis

09.10.19

Macular Degeneration Conference Series in the Spotlight

Source: Macular Degeneration Association

09.09.19

Allergan and Molecular Partners Announce Acceptance of FDA BLA for Abicipar Pegol in Patients With Wet AMD

Source: Allergan

09.04.19

Regenxbio Announces License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314

Source: Regenxbio

08.20.19

Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DME

Source: Aerie Pharmaceuticals

08.09.19

Regenxbio Reports Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMD

Source: Regenxbio

08.08.19

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD

Source: Opthea

07.29.19

Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpoints

Source: Alkahest

View more stories